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Background
Anticoagulation is a prescribed therapy that thins a patient’s blood in order to treat certain
diagnoses or prevent the occurrence of certain events. The most common indications for
anticoagulation therapy are to treat or prevent clotting disorders such as pulmonary emboli (PE) or deep
vein thrombosis (DVT) and embolic stroke from irregular heart rhythms such as atrial fibrillation. Points
of entry and methods for managing this treatment may vary within a single healthcare system, and
without a systematic approach and standardized protocols, patients may not receive optimal treatment.
Anticoagulation is unique to many treatment therapies because the most commonly used medication in
treatment, warfarin (or Coumadin/Jantoven), has a relatively narrow therapeutic range and requires
frequent dose adjustments based on the close monitoring of blood draws. The lab value used for
monitoring the therapeutic effect of treatment is the prothrombin time/international normalized ration
(PT/INR) which indicates serum clotting time. Potential risks associated with poor dosage control
include hemorrhagic and thromboembolic events such as stroke and pulmonary emboli (PE). Transitions
in care, medical procedures, surgeries, antibiotics, and changes in diet can further complicate treatment
efforts and require more frequent monitoring and dosage changes. Coordination of care through
integrated delivery systems is essential to the management of these patients.

National Awareness:
Over the past decade there has been an increased focus on the safety and management of
patients receiving anticoagulation therapy. In 2008, The Joint Commission added an additional safety
requirement to the National Patient Safety Goals specifically addressing the use of anticoagulation
therapy (NPSG 3.05.01). This new standard focuses on the need for patient education and the use of
approved protocols and policies. The National Quality Forum Safe Practice 29 also focuses specifically
on the safety of anticoagulation therapy and performance measures surrounding quality improvement
efforts. (NQF, 2010) Further efforts by the Institute for Safe Medicine Practices (ISMP) have created
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additional resources for hospitals that are available as an online toolkit and includes items such as a self‐
assessment tool and sample failure modes and effects analysis (FMEA) for hospitals to assess their
ability to provide high quality anticoagulation therapy in a safe and effective manner (ISMP, 2014).

Problem
The Mercy Health System of Maine (MHSM) is a large healthcare system located in Southern
Maine. It consists of three inpatient campuses, one level II Emergency Department, four Express Care
centers, seven Primary Care locations and an array of specialist practices. The organization has
identified a need for improved management of anticoagulation therapy within the system as a large
number of patients are receiving anticoagulation therapy throughout all of the various healthcare access
sites. In order to address this need, MHSM seeks to implement a system‐wide, standardized approach
for managing patients receiving anticoagulation therapy.
In April of 2014, MHSM approved a plan to implement an anticoagulation management service
(AMS) based in the cardiology practice. This service will initially see patients at the cardiology practice
site and then begin to serve patients at selected outlying practice sites on certain scheduled days as
well. The AMS will first consist of any existing anticoagulated cardiology patients as well as any
inpatients being discharged from the hospital with a new prescription for anticoagulation therapy. Once
the program is established, further enrollment will aim to provide services to additional patients in the
Mercy System from the primary care sites via a referral approach. The organization is in the process of
developing the clinical policies and protocols and obtaining necessary resources to establish and
mobilize a system‐wide approach. There is a need for a strategic plan for implementation to identify
current processes, key players, and necessary human and technological resources. Additionally,
determining structural and operational practices will allow clinicians to deliver patients with optimal
anticoagulation therapy. Incorporating these practices into the development plan will ensure that the
organization best serves the needs of the population receiving care at MHSM.
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Methods
The approach for the study is a qualitative review of the evidence in relation to current practices
throughout the system and identification of future considerations for implementation. In order to
adequately assess the scope of the project and the areas for development, a close look at what currently
exists in the system in relation to what evidence recommends as best practice has been performed
based on the chronic care model with a specific focus on the following four core elements of this model:
1) delivery system design, 2) clinical information systems, 3) a prepared and proactive team, and 4)
informed activated patients (Wagner et al., 2001). With these four elements in mind, a review of the
literature was conducted and questions were developed to interview staff at each of the nine outpatient
sites currently managing patients on chronic anticoagulation therapy. The interviews were performed in
conjunction with a field experience opportunity in which practice sites were visited and staff provided
information on how current anticoagulation therapy is currently being managed. Interviewees included
physicians, RNs/LPNs, MAs and practice managers from eight of the nine sites (one practice sites was
unable to be scheduled in time for inclusion in results). Through an analysis of the interviews and
information from the site visits, and in collaboration with the project’s business and clinical teams
(which consists of the physician champion, cardiology practice manager, and pharmacy director among
others), the following tools construct the framework for the project: 1) a thorough literature review for
evidence based practice, 2) a logic model identifying project resources, inputs and outputs, and
outcomes, 3) process maps of both current and future work flows, 4) an evidence‐based gap analysis, 5)
an organizational readiness assessment, 6) a patient‐centered care model, and 7) additional
recommendations pertaining to education, documentation, patient engagement, and operational
considerations. These tools will assist and guide the organization in designing a system‐wide, evidence‐
based strategic plan for implementing an anticoagulation management service (AMS) that will meet
program goals during all phases of implementation.
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Literature Review
In order to identify best practice recommendations and existing operational considerations for
implementing an anticoagulant management service, a review of the literature has been conducted to
address the following points:
1. Standards for best practice and the identification of factors known to contribute to health
outcomes for patients receiving anticoagulation therapy.
2. Staffing considerations, resources and the necessary key players for success.
3. Operational and organizational recommendations for providing high quality anticoagulation
management.
The findings from the literature review provide the foundation for the gap analysis and are the basis
for the recommendations of a strategic plan that will aim to reach all MHSM patients on anticoagulation
therapy.
As the literature review focuses primarily on areas of research pertaining to the implementation of
an anticoagulation management therapy program, a search of PUBMED, CINAHL and Google Scholar
databases was conducted using the key terms: anticoagulation therapy, anticoagulation management,
outpatient anticoagulation management, anticoagulation clinic, and operational anticoagulation.
Articles were then reviewed to look specifically for evidence‐based guidelines for managing
anticoagulation services. Relevant citations were also reviewed for further information and the
following recommendations were identified.

Review of Evidence Based Guidelines:
Systematic approach: Possibly the most widely recognized method for increasing safety and
efficiency in anticoagulation therapy is the creation of a system‐wide, evidence‐based approach for
managing care. And as described by Garcia et al. (2008), this is often implemented through a dedicated
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anticoagulation management service (AMS). However, these authors also note that this is not how the
majority of patients in North America are currently receiving this care (Garcia et al., 2008). The positive
impact on quality metrics for patients receiving therapy through a centralized service as compared to
usual care has been well studied and published for over twenty years (Chiquette, Amato, & Busey,
1998), (Witt, Sadler, Shanahan, Mazzoli, & Tillman, 2008), (Baker, Cios, Sander, & Coleman, 2009),
(Wilson et al., 2003).
Qualifications and Supervision of Staff: Another recommendation for ensuring high quality
anticoagulation therapy is the training and supervision of staff involved in the care of patients receiving
therapy. Specifically it has been suggested that patient assessment and therapy management should be
administered only by licensed healthcare professionals who have received formal education and training
on anticoagulation therapy management (Garcia et al., 2008). For practitioners or organizations that
may be working with a referring provider to manage patient care it is encouraged that a collaborative
practice agreement be established in order to clearly define the roles and responsibilities of the
healthcare team (Garcia, et al., 2008).
Care Coordination: In order to best identify, track and manage patients a great deal of focus
should be placed on the specific care coordination efforts within any management service. This includes
the development of policies and procedures and documentation and tracking systems that facilitate
access to information and monitoring of quality data. Specific items that may be addressed by policies
and procedures include: risks and benefits of therapy, patient’s understanding, indications, target INR
values, planned duration of therapy, managing initiation of therapy, management of non‐therapeutic
INR values, monitoring intervals, definition and documentation of adverse events, method for follow‐up
of missed appointments, timely reporting of lab results, managing transitions or interruptions in care,
managing non‐adherence, developing criteria for discharge, reimbursement, quality measures,
management during pregnancy, and eligibility criteria for patient self‐testing (PST) (Garcia et al., 2008).
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A tracking system that promotes documentation of desired elements and facilitates quality
measurements should include patient demographics, treatments, and communication with the patient
including education (Garcia et al., 2008).
Patient Assessment and Education/Communication: As described above, policies and
procedures and documentation/tracking systems should help guide clinicians in the assessment and
education of patients. The initial patient assessment should include a comprehensive medical history,
social, employment and lifestyle profiles, as well as the patient’s beliefs, attitudes, level of
understanding, health literacy, resources, and motivation (Garcia et al., 2008). Knowledge assessment
tools specific to anticoagulation have already been utilized and proven to be of value and may be helpful
for providers in establishing education needs for individual patients (Garcia et al., 2008), (Briggs,
Jackson, Bruce & Shapiro, 2005). Documentation of patient communication and the management of
missed appointments or changes to plans of care are also recommended (Garcia et al., 2008)
Quality Metrics: Time in therapeutic range (TTR) is the most widely reported and recognized
quality metric for evaluating patient management. Significant research has been conducted on the
impact TTR has on patient outcomes and rate of mortality. It is well documented in the evidence that
time spent out of therapeutic range is strongly correlated with increased incidences of hemorrhagic and
thrombotic complications associated with anticoagulation therapy and an increase in TTR has been
associated with decreased mortality, myocardial infarction, and stroke (Witt et al., 2008) (Phillips &
Ansell, 2008). Current recommendations for the proportion of patients INR time spent in therapeutic
range should be around 60‐70% (Phillips & Ansell, 2008). The frequency of INR testing is recommended
as every four weeks once stable and at least every two weeks for unstable patients, with no more than
one week elapsing after an out of range INR (Phillips & Ansell, 2008). Once dosing has been established
and the INR has been therapeutic for greater than three months the INR can be monitored every eight
to twelve weeks thereafter (Holbrook et al, 2012). The other well accepted and reported quality metric
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is the rate of adverse events including hemorrhage and thromboembolism, which can also be tracked
and evaluated in comparison to recommended benchmarks. As suggested by Phillips and Ansell (2008)
overall rates of hemorrhagic and thromboembolic events in established patients should be no higher
than 1‐2% per patient year. Most importantly, continuous tracking of quality metrics assessed by a
consistent method is recommended within any setting where anticoagulation therapy is being managed.
Initiation/Maintenance of Therapy: Another prominent practice recommendation in the
literature is the establishment of system‐wide evidence‐based protocols that clearly define the actions
to be taken during the initiation phase of therapy and subsequent treatment changes throughout the
course of therapy. Clinical practice guidelines are well established and frequently reviewed and
published and are already widely in use. Identification and standardization of a protocol for system‐
wide use improves coordination across transitions of care and ensures that all providers within a system
are working from the same tool. The American College of Chest Physicians published evidence‐based
practice guidelines on managing Vitamin K Antagonists in 2008 and in 2012 released evidence‐based
clinical practice guidelines on antithrombotic therapy and prevention of thrombosis which both outline
in detail the clinical practice recommendations for managing anticoagulated patients.

New Areas of Research:
Process Measures and Operational Indicators of Quality: In addition to quality metrics
ensuring the effectiveness of clinical management services, there is newer research that aims to assess
the operational aspects of anticoagulation management services by focusing on structural and process
measures. This research points out that while there are ample examinations of the clinical and patient
care aspects of anticoagulation therapy, little attention has been paid to what managerial and
operational practices impact patient outcomes. In 2009 The Joint Commission (Rose et al., 2009)
released a performance improvement article describing methods for assessing the quality of operational
functions of systems providing anticoagulation management services to patients. This article describes
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indicators addressing both the structure of the service where the care is provided, how INR results are
collected, and tracking software, as mentioned above as well as process measures such as time to
initiation of therapy, maximum time for INR testing after initiation, and timeliness of follow up patient
notification when an INR falls outside an acceptable range. The article also identified the need for
further research to correlate structural and process indicators with clinical quality data to evaluate the
impact that different operational variants may have on patient outcomes.
Following the release of the Joint Commission article, two additional studies have been
conducted both within the Veterans Health Administration (VA) facilities. The first published in 2011
(Rose et al, 2011) sought to identify specifically which organizational and management features could be
associated with better clinical outcomes. The authors surprisingly found no statistical significance for
any of the current clinical guidelines that have been recommended to date in the literature. However,
the results of this study then spurred on a second qualitative study by Rose et al., (2012) that compared
three of the highest performing anticoagulation clinics (ACCs) with three of the lowest performing ACCs
in the VA. From this information alternative domains of organization associated with level of
performance were identified and described. The six domains that were found to be significant include:
1) sufficient staffing to handle workload, 2) innovation to encourage EBP, 3) presence of a quality
champion, 4) residency‐trained pharmacists, 5) creating a climate of group learning, and 6) internal
performance measurement.

Additional Areas of Research:
While not reviewed in depth at this time the following areas of research were identified as
frequently recurring themes and may be of interest to key players in the project:
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Calculation of Quality Metrics for Clinical Outcomes: Three methods for calculating time in
therapeutic ration (TTR) were tested in a study by Schmitt et al. (2003). The results found that all three
methods of calculating TTR possessed inherent limitations, and the authors identified that while this
makes large scale comparisons of clinical outcomes across studies difficult it is important that
investigators select one method and remain consistent in their techniques.
Design Methods Impacting Quality: Studies have indicated that the method for INR monitoring
can influence metrics including the TTR, and specifically that the utilization of POC devices, which can be
done at locations where laboratory access is an issue, may improve clinical outcomes due to the ability
to provide patients with more frequent and easier access to testing (Franke, Dickerson, & Carek, 2008).
Other studies have focused on the accuracy of POC devices and provide recommendations for periodic
equipment testing (Sunderji et al., 2005) and the need for an established range for validation of out‐of‐
range INR results (Dorfman et al., 2005).
Models of Care: Since at this time the decision has been made to initially implement a facility
based anticoagulation management service, the location specific models of care including usual medical
care (UC), Anticoagulation Clinic (AC), Patient Self‐Testing (PST), and Patient Self‐Monitoring (PSM) were
not explored in depth. It is important to note however that the model of care has been found to impact
factors including but not limited to: frequency of testing, patient satisfaction, cost, and quality metrics
including TTR.
Peri‐operative Management: While not discussed in depth for the development of an
anticoagulation management service, there is a great deal of research concerning the topic of peri‐
operative anticoagulation which is often used as a prophylaxis for prevention of thrombotic adverse
events related to surgical procedures.
Future Considerations: New medications for anticoagulation therapy have emerged over the
past several years, and this has implications for clinic models and recommendations for clinical
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management for all providers. The new oral anticoagulants work using a different mechanism of action
than warfarin by effecting a different segment of the clotting cascade, because of this, they do not
require INR monitoring. A recent article by Burnett and Trujilo (2013) outlines how these new therapies
might impact practice and what can be expected in the coming years.

Logic Model
MHSM will be implementing the anticoagulation management program in a phased method,
beginning first with existing cardiology patients and any patients discharged from the hospital with a
new prescription for an anticoagulant. As the project advances through the phases of implementation it
is vital that there is an assessment of progress based on the initial goals and outcomes. To aid with this
evaluation and to begin the identification of inputs and outputs, strategies, and outcomes a logic model
was created (see Appendix A).

Process Flows
Process mapping of the current flow of anticoagulated patients throughout the system enables
the organization to analyze existing processes, strategies currently being utilized, variations in practice,
and opportunities to streamline workflow for consideration in future planning. Process mapping the
future work flows allows the project team to begin identifying and addressing any points in the process
that could potentially be problematic. This will define current access points for patients, identify
barriers, and help clinicians understand the flow of patients through the care continuum. For instance,
current management of anticoagulation therapy is provided either by the prescribing provider or the
PCP, in an AMS model, steps for referral and the transfer of patient care would need to be discussed and
worked out prior to opening. See Appendix B for process maps of current work flow and Appendix C for
process maps of potential future work flows.
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Gap Analysis
Utilizing the Agency for Healthcare Research and Quality (AHRQ) Gap Analysis Tool (Toolkit,
2012) each area of evidence‐based practice, along with new considerations for operational and
organizational areas of performance related to high quality anticoagulation care as studied by Rose et al.
(2012) were evaluated in contrast to current practices within the MHSM outpatient areas. The key
areas for consideration resulting from the gap analysis include: the need for standardized clinical
protocols, policies and procedures, patient assessment and education needs, documentation and
tracking capabilities, safety practices and quality measurement, and resources to encourage innovation
and evidence‐based practice. Please see Appendix D for complete results and recommendations.

Organizational Readiness
Based on interviews and information gathered during the field experience, an assessment of the
organizational state of readiness was performed (see Appendix E). This information allows the
organization to identify which key actions need to be performed prior to moving forward with the
project implementation and whether or not implementation is feasible at this time. The readiness
assessment yielded a recommendation is to move forward. The key actions items include:


the hiring and training of staff



the purchase of necessary equipment



distribution of a patient letter/survey to engage patients in the process change (see
Appendix F)



creation of an Anticoagulation Council to support the project on an ongoing basis



development of policies and procedures



collaboration with key stakeholders (specifically the Director of Primary Care to establish
location of services)
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supplying the primary care providers with education in regards to referral process.

A care model has been created in order to identify the many individuals and teams who would
play a role in managing the care for an anticoagulated patient. The Chronic Care Model (Wagner, 1998)
provides a useful framework to display visually the key players and the points at which they interact.
Included in the model are the recommended actions for maximizing the roles and connections between
the key players and the areas of the model they correspond to (see Appendix G).

Documentation and Quality Design
Recommendations for documentation and assessment of quality metrics have been developed
based on evidence obtained from the literature review and will serve to help inform the decisions of the
organization when addressing aspects of the system design. At MHSM the outpatient physician
practices utilize an electronic documentation system (or electronic health record‐EHR) and the
functionalities of this system were investigated during the interview process. The following areas were
discussed for feedback from MHSM clinicians: patient identification and assessment information,
process flows for the input and tracking of clinical data (including labs and dosage changes), patient
education practices, procedures during transitions of care, and the process for patient follow up
communications.
Through a review of the information gathered during the interviews, current documentation
elements being recorded in the EHR, and those that are being recorded elsewhere (either on paper or in
supplemental documentation tools) are outlined in table 1. Recommendations for the necessary
components that incorporate evidence‐based practice elements into patient assessment and
documentation are listed in table 2. The area of concern most frequently expressed during the
interviews is the inability of the EHR to provide system‐generated data to assist in the tracking and
monitoring of patient INRs, missed appointments, and overdue labs. Currently there is no report or
reminder that allows clinicians to review which patients may have missed having an INR. Several
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different strategies have emerged to address this need including paper charting, manually updated excel
tracking spreadsheet, manually created reminder tasks, and paper tracking tools.
In regard to quality monitoring, there is also no system‐generated quality measurement data,
and the process for obtaining the data is manual and cannot be accessed through the EHR for all
anticoagulated patients because some documentation of INR values is still on paper. Manual tracking of
quality measures is not being performed at this time. Quality metrics will need to be assessed in order
to further evaluate current practices. Once this is done, the organization will be able to compare the
quality of current anticoagulation therapy to any future efforts throughout the implementation phases
of the project. Recommended baseline quality metrics for tracking progress includes the two widely
accepted clinical quality metrics of time in therapeutic range (TTR) for patients’ INR values and the rate
of adverse events such as hemorrhage/bleeding and stroke. In addition to these important
benchmarking measures, it is strongly recommended that operational metrics for measuring internal
performance measures of practice are considered and built into any future assessment fields. This could
include measures such as time taken to contact patients, time from referral to first appointment,
number of patients discharged, and percent of scheduled tests completed.
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Table 1. Examination of Documentation Elements
Documentation Items Currently Captured in the Existing Electronic Health Record Anticoagulation
Flowsheet:
 INR
 Current dose
 New dose
 Recheck
 Pt notified
 Comments
Documentation Items not captured in Electronic Health Record:












Provider managing INR
INR goal
Indication
Method of testing
Tablet Strength
Patient Instructions
Education
Physician signature
Necessity for anticoagulant bridging
Outstanding labs/Coumadin agreement
Patient letters
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Table 2. Recommendations for Assessments (Ansell, Oertel, & Wittkowsky, 2009)

Recommended Assessment Fields
New Patient Education:
 Reason/indication for anticoagulation
 How anticoagulants work
 Importance of adherence with dosing
and appointments
 Dosing and administration
 Tablet strength‐with visual recognition
 What to do for a missed dose
 Different names of anticoagulant
 Potential drug interactions
 Avoidance of NSAIDS and Aspirin
 Activities/Fall precautions
 Dietary and alcohol considerations
 Importance of laboratory/clinic
monitoring
 Signs of bleeding
 Signs of disease recurrence
 What to do in case of bleeding
 Plan for length of therapy
 Interruptions in therapy for
surgical/invasive or dental procedures
Travel
considerations

 Informing other healthcare professionals
 Anticoagulant card or bracelet
 Tracking INR and medication list
 Emergency phone numbers
 Preferred method for contact and timely
follow up
 Refills
 Storage
 Pregnancy

Initial Intake Assessment:
 Comprehensive Medical History
 Social factors
 Employment factors
 Lifestyle factors
 Beliefs
 Attitudes
 Level of understanding
 Health literacy
 Resources
 Motivation
 Care Contract

Education for established patients:
 Adherence
 Actual dose taken
 S&S of bleeding/bruising
 S&S of disease recurrence
 Diet changes
 Alcohol use
 Change in prescriptions/OTC/herbal
medications
 Recent illnesses
 Surgical/invasive or dental procedures

Education to be covered at every visit:
 INR
 Therapeutic or not
 Dosage change
 When to call office
 What to do in case of bleeding
 Date of next appointment
 Reading ability
 Written instructions/calendar
 Teach back/patient understanding
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Results
As a result of examining current practice and evidence‐based practice, the gap analysis reveals
many opportunities for improving the care of anticoagulated patients within the MHSM system. While it
was evident during the interviews that providers are doing the best they can with the resources
currently available to them, multiple barriers have been identified. The two primary barriers are a lack
of system‐wide policies and procedures to help guide clinician in clinical decision making and
management of care, and information systems that don’t allow for tracking of patient data or quality
monitoring.
Currently, patients in the system are managed by providers across multiple settings with varying
methods for communication regarding the management and coordination of the patient’s INR. While
providers report utilizing dosing standards consistent with clinical guidelines there is no written protocol
to guide clinical decision making including determining which patients may need bridging for invasive
procedures. The term ‘bridging’ refers to the need to place a patient on an alternate anticoagulant with
a shorter half‐life than warfarin, such as enoxaparin subcutaneous injections, in order to safely perform
invasive procedures. There are no reports or tracking tools available to clinicians that pull patient data
from the anticoagulation flowsheet in the EHR where the majority of practices are documenting
information. Some practices currently provide onsite laboratory services for patients which may help
with compliance, especially in the more rural areas. However, because lab results come into the
practices from a variety of settings including Mercy‐owned labs, laboratory facilities outside of the
Mercy system, the Visiting Nurses’ Association point of care tests, and patient self‐testing monitors,
manual data entry is occurring in a variety of ways that makes tracking current data and therefore
quality especially challenging. In an effort to overcome this some practices have established manual
ways to create reminders and prompts for following up with patients with outstanding labs or who are
non‐compliant. Clinicians acknowledge that some patients may go longer than recommended between
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INR draws and the procedure for then managing these patients also varies among sites of care. Based
on these findings and research, the following recommendations have been created:


Continue implementation of a system‐wide Anticoagulation Management Service




Proceed in a phased approach starting with cardiology patients

Form an anticoagulation council


To provide oversight during the development/implementation of policies and
procedures (for both the AMS program as well as system‐wide practice)



Develop policies and procedures to guide anticoagulation practices


Address system‐wide dosing standards, bridging therapy, and referral policies to
the AMS program



Engage patients during subsequent phases of implementation


Obtain patient consent for referral to the AMS program



Provide patients with additional options for location of care to encourage
patient engagement



Consider utilizing a patient contract for anticoagulation care to inform and
educate patients on the importance of follow up and the process for missed
labs/appointments



Involve patients in the program development process




Solicit feedback through a patient letter or survey

Address educational needs at the system‐wide level


Develop evidence‐based tools to address educational assessment of
anticoagulated patients




Create tools for ongoing education reassessment

Explore EHR system capabilities
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Create a report to be generated for tracking data and quality monitoring



Provide education on the use of these tools to practices for immediate
enhancement of patient tracking



Use this information to begin reviewing and monitoring quality, provide this
information to the practices



Consider ongoing needs for documentation and assessments


If assessment fields and quality monitoring cannot be captured in the current
EHR the organization may want to explore software programs for purchase





Develop and utilize internal performance measures of quality


Timeliness of patient follow up



Time to first appointment (for the AMS)



Percentage of missed appointments

Implement point of care testing


Start with the AMS program



Enhance time spent with patients during appointments by taking results from
point‐of‐care tests and incorporate into real time education on significance of
results and dosing changes, use this opportunity to allow for patient questions
and teach back

Discussion
The creation of a centralized program responsible for the identification and development of
resources is the first key step to implementing a system‐wide approach. From the organizational
readiness assessment, it is clear that the MHSM organization is ready for this change. Based on the
feedback gathered during the interview process, it is evident that clinicians are looking for the additional
tools and resources to enhance care for anticoagulated patients. It is important that during the initial
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implementation phases that patients themselves are also engaged in the process as any new
developments, whether through system‐wide policies or referrals to the AMS program will directly
impact their current care. It is strongly recommended that the organization seek input regarding
potential areas of improvement directly from the patients in order to ensure that the model will provide
patient‐centered care. The development of the program, including hiring and training of clinicians, the
composition of policies, and the acquisition of necessary equipment will be a significant undertaking.
And while this may consume the majority of available project resources, it is crucial that in the early
stages of implementation the project team strive to identify short‐term actions that can immediately
improve patient care in all practice settings. These immediate changes will ensure that patients are
receiving the necessary lab monitoring and therapy management prior to the implementation of
subsequent phases of the project.
Establishing the capabilities of the EHR will also be essential in providing the outpatient areas with
the tools to determine which patients may have outstanding labs and to help to establish baseline
quality metrics. The investigation into the possible generation of reports for patient tracking should be a
top priority for the improvement of anticoagulation care. Once these reports are available in the
system, baseline quality metrics should be established in order to evaluate the quality of current
practice. This will allow for the evaluation of subsequent phases of the project. If these reports cannot
be run retrospectively it is highly recommended that resources be allocated to manually gather data in
order to identify a starting point for quality enhancements.
Aside from clinical quality measures such as TTR, internal performance measurement of indicators
such as missed appointments, patient discharges from the program, and timeliness of first appointment
after initiation of therapy, should be considered as any new documentation capabilities are being
created. It is also worth mentioning that due to the complexity of the clinical dosing guidelines, the
depth of educational and patient assessment topics, and the importance of patient understanding, it
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may not be possible to build the necessary documentation requirements into the current EHR.
However, there are many resources and software programs available and investment in this type of
software should be a consideration.
One strength of this project is the wide availability of clinical guidelines and additional resources.
There are web‐based clinical decision tools for calculating dosage changes that are free and have been
endorsed by well‐established, high‐performing anticoagulation clinics. The Anticoagulation Forum is an
organization that focuses on anticoagulation therapy and their website has many links and resources to
sample policies, guidelines, and current research. There is also an Anticoagulation Center of Excellence
that offers certification that can be found through the Anticoagulation Forum website. The
Anticoagulation Center of Excellence provides clinics with an assessment tool to apply for recognition as
well as feedback on areas for improvement to obtain recognition as a center of excellence. Membership
to the anticoagulation forum is free and all of these resources are easily accessible.
It is clear that there is a desire amongst clinicians to improve the management of anticoagulated
patients throughout the system, and based on regulatory standards, it is imperative that steps are taken
toward improving the safety of administering anticoagulation therapy. The range of services, the
methods for implementation, and the extent to which the project executes processes to ensure optimal
quality still need to be established, but the recommendations and action items discussed above may be
used to help guide and inform these decisions as the organization moves forward. Given the complexity
of the anticoagulated patient, and the importance of the patient’s educational needs and level of
understanding, it is essential that care be coordinated in such a way that the very serious risks of poor
management are minimized. The potential impact of this program on patient care and health outcomes
is promising. The success of the program can be accomplished through the incorporation of patient‐
centered services, additional educational and technological resources, and a goal‐oriented team focused
on anticoagulation.
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Improving Health Outcomes through a System‐Wide Approach to Anticoagulation Therapy
Inputs

Human








Patients
Referring Providers
Pharmacist
Cardiologist
RN
Practice Manager
Dietician

Strategies

Outputs

Development of
Evidence Based
Policies and Protocols
for use in the Mercy
System

Policies and Protocols
Established

‐Medical/Cardiac Therapy
‐Peri‐operative Therapy





Implementation across
healthcare system for
all patients requiring
anticoagulation
therapy
Easily attainable
online to healthcare
providers

Short‐Term
Outcomes
Policies and Protocols
online and available to
all Mercy primary care
physicians and
providers with
privileges at Mercy
Hospital through the
physician portal

Intermediate
Outcomes

Increase percent of
time in a
therapeutic range
among Mercy
managed patients

Financial



MHSM funding
Reimbursement
through Insurance
Claims

Infrastructure




Patient Data from
Allscripts/Meditech
Tracking software
program (?can this be
created in Allscripts)
Potential space for
clinic(s)

Community





Surgical LLC’s
Local surgeons with
privileges at Mercy
Local pharmacies
Care Managers and
Care Navigators from
across the EMHS
system

Create a tracking
system and enroll all
patients requiring
anticoagulation
therapy that enter the
Mercy system

Tracking System
Established





Develop a business
plan for a model that
will best support the
attainment of the
desired population
health outcomes

Clinic Model
Implemented




Implement a
marketing strategy
that will create
awareness amongst
referring physicians
and patients in the
community

Data interfaces
created
Patients enrolled
Baseline data collected
for future evaluation
Provider view access

Staff hired and hours
of service determined
Model meets the
needs of the
population
Evidence based model
with a focus on
improving population
health outcomes

Marketing Campaign
Launched


Referring physicians
and patients aware of
services provided

Tracking of all Mercy
managed
anticoagulated
patients throughout
the system

Increase in patients’
awareness and
treatment adherence
through education
and
physician/RN/dietician
consults

Increased number of
follow up
arrangements made
within 48 hours for
patients with missed
appointments

Decrease in the
percentage of
patients with an
outstanding INR

Increased patient
satisfaction for
patients receiving
anticoagulation
therapy

Long‐Term
Outcomes

Improved
management of
anticoagulated
patients throughout
the continuum of care
within the Mercy
System

Decreased adverse
events and mortality
for anticoagulated
patients

Improved
population‐
based health
outcomes

External Factors Impacting Outcomes
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Gap Analysis
Project: Implementation of an Evidence‐Based System‐Wide Anticoagulation Management Service at Mercy Health System of
Maine
Prepared by: Sarah Varney, RN, BSN
Best Practice: As Mercy has received approval to begin the development of a system‐wide anticoagulation management
service it is crucial to establish what best practice strategies currently exist, how these differ from current practices, what
barriers exist to implementation of these best practices, and how the implementation of this program would address these
areas of practice. Best practice recommendations were identified through a review of regulatory and expert, evidence
based publications from sources including The Joint Commission, the Board of Directors of the Anticoagulation Forum,
expert reviews, and current original research.
Best Practice

Best Practice Strategies

How Your Practices Differ From Best
Practices

Barriers to Best Practice
Implementation

Ensure that
anticoagulation
therapy is effective
and safe (NQF,
Safe Practice 29)

The use of approved protocols for
the initiation and maintenance of
anticoagulant therapy.

No standard protocol selected for use
in the outpatient setting at this time.

Compliance across multiple
settings may be difficult
unless centralized
management service
developed.
Barriers include the ability
to document these aspects
of coagulation status in the
electronic health record
(EHR).

Before starting a patient on
Reduce the
warfarin, assess baseline
likelihood of
coagulation status and document in
patient harm
the patient record.
associated with the
use of
anticoagulant
therapy (NPSG
3.05.01)

The baseline INR is currently being
captured in the patient record.
However, there is no consistent
method for documenting indication,
INR goal, tablet strength, whether or
not anticoagulant bridging would be
required for procedures, and who is
managing the anticoagulation therapy.
This information is typically flagged or
documented in notes but finding this
information can be difficult and it is
not consistently documented clearly.

Will Implement
Best Practice?
(Yes/No Why not?)
Yes

Yes
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Use authoritative resources to
manage potential food and drug
reactions for patients on warfarin.
A written policy addresses baseline
and ongoing lab tests required for
anticoagulants.
Provide education to prescribers,
staff, patients and families.
Patient/family education includes
the following: the importance of
follow‐up monitoring, compliance,
drug‐food interactions, the potential
for adverse drug reactions and
interactions.
Evaluate anticoagulation safety
practices, take action to improve
practices and measure the
effectiveness of those actions in a
time frame determined by the
organization.
Qualifications and
Patient assessment and therapy
Supervision of Staff management provided by licensed
(Garcia et al., 2008) healthcare professionals who have
received formalized training.

Education resources and protocols for
outpatient setting vary and are
inconsistent.
No current outpatient policy.

Educational resources vary throughout
practice settings. The educational
material for patients is inconsistent
across the organization.

There is no current structure in place
to look specifically at anticoagulation
safety and there is difficulty extracting
data from the current EHR to evaluate
effectiveness of improvement
initiatives.
Currently assessment and therapy is
managed by either the specialist
prescribing or the primary care
provider, while all are licensed
healthcare providers trained in patient
assessment and care there is no
formalized process across the system
for additional training on
anticoagulant therapy.

Identification and
dissemination of resources.

Yes

Creating policy and
educating providers will
take time.
Education is currently
being provided primarily by
the physicians and some
RN/MAs. Educational
materials will need to be
created and disseminated
to all potential areas of
care and to all providers
and staff.
The EHR will need to be
altered or a report will
need to be created in order
to track and evaluate
effectiveness of
anticoagulation safety
practices.
The primary barrier at this
point in time is that
anticoagulation therapy is
being managed by a
multitude of different
providers across many
different care settings
which make formalized
training difficult to
administer. The creation of
a dedicated AMS would
alleviate this barrier.

Yes

Yes

Yes

Yes
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Care Management
and
Coordination/Docu
mentation (Garcia
et al., 2008)

Collaborative practice agreement
when working with referring
providers.

As there is not currently a dedicated
AMS no such collaborative agreement
exists at this time as it is not necessary
since there are no referrals specifically
for anticoagulation management.

Organization should have
established policies and procedures
that address the following areas:
risks and benefits of therapy,
patient’s understanding, indications,
target INR values, planned duration,
managing initiation of therapy,
management of non‐therapeutic INR
values, monitoring intervals,
definition and documentation of
adverse events, method for follow‐
up of missed appointments, timely
reporting of lab results, managing
transitions or interruptions in care,
managing non‐adherence, criteria
for discharge, reimbursement,
quality measures, management
during pregnancy, eligibility criteria
for patient self‐testing (PST).
Utilization of a tracking system to
promote documentation of desired
elements and facilitate quality
measurements including
information such as patient
demographics, treatments,
communication and education.

These policies have not yet been
approved for the outpatient setting at
the system level.

While this data is entered into the
system at this time there is no
mechanism for tracking or generating
reports from this information in order
to track patients or monitor quality
data.

As an AMS is developed
this should be a
consideration, barriers
would be limited to time
and resources to work on
putting an agreement in
place.
Barriers include staff and
resources available to work
on the development of
these policies and approval
from authoritative councils
(Pharmacy and
Therapeutics, Medical
Executives).

Barriers include IT
resources and analysts to
develop the capability of
the system to generate a
report or reminder
function to aid in the
tracking of patient
information such as next

Yes

Yes

Yes
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Patient
Assessment and
Education/Commu
nication (Garcia et
al., 2008)

Laboratory
Monitoring/
Initiation &

Initial patient assessment consisting
of a comprehensive medical history,
social, employment and lifestyle
profiles, as well as the patient’s
beliefs, attitudes, level of
understanding, health literacy,
resources, and motivation.
Knowledge assessment tools specific
to anticoagulation that establishes
education needs for individual
patients.

While providers may cover these areas
in their patient visits there is not a
formal assessment for the
anticoagulation patient.

Documentation of patient
communication and the
management of missed
appointments or changes to plans of
care.

Documentation of patient
communications and missed
appointments is currently recorded in
the EHR, some sites have created
processes for managing patients who
miss appointments but there is no
standardized system‐wide process in
place and many sites identify this as a
needed resource.

Periodic review of treatment plan
for appropriateness throughout
course of therapy.

While this may be occurring there is
no formal documentation or
established policy to support this.

Proportion of patient INRs time in
therapeutic range measured using
consistent methodology (Phillips &

This is not currently being measured in
the outpatient setting at this time.

There is no consistent tool identified
for use at the system level at this time
in the outpatient setting.

INR due and overdue INRs.
One existing barrier would
be that any patient
assessment tools would
need to be incorporated
and built into the EHR.

Minimal barriers identified
as this could be performed
using a paper tool and the
results documented in the
EHR.
Minimal barriers as the
ability to document this
information exists currently
however a system‐wide
policy for addressing
missed appointments
should be developed and
would require time for
development and approval
from appropriate decision
making councils.
There would need to be
some method for
documenting this review or
a policy outlining how this
review would be conducted
in order to ensure this
occurred.
Will need IT resources to
create the ability for the
EHR to generate this

Yes

Yes

Yes

Yes

Yes
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Maintenance of
Therapy (Phillips &
Ansell, 2008)
(Garcia et al, 2008)

Process Measures
for Quality (Rose et
al., 2012)

Ansell, 2008).
Tracking of rates of hemorrhagic and
thromboembolic events in patients
on anticoagulant therapy (Phillips &
Ansell, 2008).
Regular laboratory monitoring of
INR for anticoagulation effect
(Garcia et al., 2008).

This is not currently being measured in
the outpatient setting at this time.

information so that it can
be more easily tracked.
Will need to create a
method for recording and
tracking this in the EHR.

Yes

Currently there is no tracking system
to establish compliance of laboratory
monitoring with established clinical
recommendations.

Will need to create a
method for obtaining this
information from the EHR.

Yes

Use of a system‐wide evidenced
based protocols that clearly define
the actions to be taken during the
initiation phase of therapy and
subsequent treatment changes
throughout the course of therapy
(Garcia et al., 2008).
Sufficient staffing to handle
workload‐staff are able to work in
an organized, comfortably paced
environment with adequate support
staff, time dedicated to
anticoagulation duties.

No current system‐wide policies or
protocols in place at this time.

Resources and information
to inform policies and
support from approving
committees.

Yes

Currently providers across the system
are managing the workload in a
multitude of settings. Some providers
and staff identify that managing this
population is time consuming and
labor intensive.

Yes

Innovation to encourage EBP such as
note templates to assist in clinical
reasoning and documentation as
well as software that enhances
workflow and reduces loss to follow‐
up.

Current organizational culture
encourages innovation and this would
be a strength to the project going
forward, however specific IT
structures to enhance innovation
around anticoagulant care need to be
further developed.

Will need to identify roles
and hire and train staff to
support providing care for
this population. Will also
need to ensure as the
patient population expands
that staffing is revaluated
on an ongoing basis.
Ensuring that newly hired
staff for the AMS program
are supported/encouraged
and allowed the time and
resources needed to foster
innovation and
involvement in EBP
education and

Yes
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Presence of a quality champion.

Staff Qualifications, pharmacists
should be residency‐trained.

There has been a cardiologist
identified as the project champion
who in the beginning stages of the
project at least would serve as the
quality champion.
There is no involvement from
pharmacists in the outpatient
anticoagulation management.

Creation of a group learning climate
that allows the discussion of difficult
cases with colleagues on a frequent
basis.

Currently primary care providers are
able to discuss cases amongst their
colleagues; however, with the
management of this population being
described as time consuming and
difficult there may not presently be
ample opportunities for these
discussions to take place in some
cases.

Internal performance measurement
either through manual data
extraction or software generated
data.

Currently there is no information on
the internal performance of the
outpatient setting being measured.

conferences/training.
Support the development
of functionalities in the
EHR to enhance workflow
and encourage EBP.
No identified barriers at
this time, sufficient interest
and hiring should support
this.
The current plan is to have
an RN led model as
opposed to pharmacist led
model, with UNE pharmacy
student involvement this is
a result of resources. Note
that the study making this
recommendation looked
only at pharmacist led
models.
With the proposed team
members consisting of
dedicated formally trained
RN and MA as well as a
cardiologist and UNE
pharmacy students there
should be plenty of
opportunity and few
barriers to a group learning
environment.
Software currently does
not support the collection
of this data and the
addition of this

Yes

No‐the new
program will not be
a pharmacist led
model of care.

Yes

Yes
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functionality will need to
be explored. Manual data
in the meantime will be
labor intensive but is
recommended to gather
baseline data for current
performance prior to the
project go live.

Gap Analysis Tool adapted from AHRQ Quality Indicators Toolkit: tool D.5. Accessed on 4/16/14 at
www.ahrq.gov/professionals/systems/hospital/qitoolkit/d5‐gapanalysis.pdf
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Assessment of Organizational Readiness
Step One: Identify the Anticipated or Desired Change
Program Description: Implement a system‐wide anticoagulation management program at Mercy Health
System of Maine to improve patient outcomes.
Step Two: Determine the Current State of the Organization in Relation to the Desired
Change
1. Does the proposed project align with the organization’s current vision, mission, and strategic
plan?
 Does the project support the organization’s vision of its desired future?
 Does the project align itself with the organization’s belief of who it is, what it does, and
how it serves?
 Does the project support the organization’s approach to achieving its goals and
objectives?
Major
Barrier

Substantial
Barrier

Significant
Changes
Needed

Minimal
Changes
Needed

Alignment with Organizational
Vision/Mission
Alignment with Strategic Plan

Full
Support
X
X

Actions Required to Become Fully Ready/ Comments:
The project is well aligned with Mercy’s vision for the future and specifically seeks to address the quality
of care it provides to the population to which it serves. Also, it aligns with regulatory requirements that
aid in achieving goals and objectives.
2. Is the proposed project consistent with the organization’s values and culture?
 Is the consistent with the organization’s guiding principles?
 Does the project align with the organization’s existing beliefs, assumptions, and
expectations?
 Does the organization’s culture support innovation and clinical technology applications?
Major
Barrier

Substantial
Barrier

Significant
Changes
Needed

Minimal
Changes
Needed

Full
Support

Alignment with Organizational
X
Values/Culture
Actions Required to Become Fully Ready/ Comments:
The project is very well aligned with the Mercy values, specifically the values of community and
excellence.
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3. Are resources available to begin development of the proposed project?
 Is funding available for the initial planning activities?
 Is there staff available to work on the project?
 Are there initiatives competing against the project?
Major
Barrier

Substantial
Barrier

Significant
Changes
Needed

Minimal
Changes
Needed
X

Full
Support

Minimal
Changes
Needed

Full
Support

Resource Availability
Actions Required to Become Fully Ready/ Comments:
Funding for the project has been secured, staff needs have been identified in the business plan and
recruitment will need to occur for the RN and MA positions. Current support is being provided by the
Manager of Cardiovascular Services, the Lead Cardiologist, and a student internship. Project team
members also include the Pharmacy Director, Director of Primary Care, Director of Ancillary Services,
Allscripts analysts, and an Inpatient Nurse Manager. Competing initiatives include conversions to the
EMHS IT programs.
4. Does the proposed program have a champion?
 Is there a clinical champion for the project?
 Is there an administrative champion for the project?
 Are there leadership groups in place to foster support?
Major
Barrier

Substantial
Barrier

Significant
Changes
Needed

Identified Champion
X
Decision Maker Interest
X
Support for Initiative
X
Actions Required to Become Fully Ready/ Comments:
A cardiologist has been identified as a clinical champion for the project. The administrative champion is
the Manager of Cardiovascular services. There are leadership groups in place who are supportive of the
project, however a specific council focused on anticoagulation will need to be created to support
ongoing efforts and initiatives.
5. Do stakeholders support the program?
 What perceptions do stakeholders have about the proposed program?
 Are stakeholders educated about the proposed program?
Major
Barrier

Substantial
Barrier

Stakeholder program perceptions
Stakeholder program education
Actions Required to Become Fully Ready/ Comments:

Significant
Changes
Needed

Minimal
Changes
Needed
X

Full
Support

X
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Perceptions about the program are that revenue generated from this project will be modest but that to
provide clinically excellent care and meet regulatory requirements it is an area that needs to be
addressed. Education to the stakeholders is in the process of occurring currently, education will need to
be provided to primary care providers and leaders.
6. Who has authority over the proposed program?
 Who has to approve the project?
 Are they supportive of the project?
Major
Barrier

Substantial
Barrier

Significant
Changes
Needed

Minimal
Changes
Needed

Full
Support

Program Authority
X
Actions Required to Become Fully Ready/ Comments:
The business plan for the program has been approved by the Systems Integration Team and the Mercy
Board of Directors will be informed of the initiative.
7. What does a SWOT analysis reveal about organizational successes and potential barriers?
 What are the organization’s strengths?
 What are the organization’s challenges or weaknesses?
 Where are the organization’s business opportunities?
 Are there any barriers to the organization’s success?
Major
Barrier

Substantial
Barrier

Significant
Changes
Needed

Minimal
Changes
Needed
X

Full
Support

Internal Factors (skill sets,
strengths, weaknesses)
External Factors (opportunities,
X
challenges)
Actions Required to Become Fully Ready/ Comments:
Strengths for the project include a supportive cardiology practice with physician capacity to expand care
provided to additional patients and primary care physicians who identify the need for improvements in
the way care is provided. The Electronic Health Record is currently a barrier to the process in terms of
tracking patients but in terms of documenting patient activity it is widely used and seen as a strength in
most regards. The capabilities of the EHR to perform in a way that enhances care through a tracking
mechanism is something that needs to be explored and most likely minimal changes will need to be
made to create this functionality. Transitioning patients from phlebotomy draws for INR results to point
of care testing as is reflected in the business plan would be a strength. The greatest potential barriers
the organization faces at this time is for the competition of available resources for all projects and
specifically IT resources as the organization is in the process of transitioning to a new parent company.
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Assessing Organizational Readiness Summary
Date: 4/11/14
Organization: Mercy Health System of Maine
Brief Description of Desired Initiative:
Implement a System‐Wide Anticoagulation Management Program at Mercy Health System of Maine
to improve patient outcomes.
Record all of your answers to the previous questions in the appropriate boxes below.
Rate Readiness Factors

Alignment with Organizational
Vision/ Mission
Alignment with Strategic Plan
Alignment with Organizational
Values/ Culture
Resource Availability: Funding
Resource Availability: Human
Resources
Resource Availability: IT
Skill Sets
Internal Factors
External Factors
Program Authority
Identified Champion
Decision Maker Interest
Support for Initiative
Other Priorities

Not Ready‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐Ready
Full
Major
Substantial Significant Minimal
Support
Changes
Barrier
Barrier
Changes
Needed
Needed
X
X
X
X
X
X
X
X
X
X
X
X
X
X

Overall Rating
List of Actions Require to Become Fully Ready:
□
□
□
□
□
□

□

Hire and train staff
Purchase Point of Care Equipment
Patient letter/survey to engage patient
in the process change
Create an Anticoagulation Council
Finalize policies and procedures
Collaborate with the Director of Primary
Care to establish location of services
provided
Provide PCP/FNP with education in
regards to referral process

X
RECOMMENDATION:
□ Move Forward Now
□ Make Necessary Changes and Reassess in
_______months
□ Not Appropriate
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Assessment of Organizational Readiness adapted from:
California Telemedicine and eHealth Center Discovery Series Assessing Organizational Readiness (2009).
www.CTEConline.org. Accessed from
http://www.hrsa.gov/quality/toolbox/methodology/readinessassessment/part4.html
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Date

Mercy Hospital
144 State Street
Portland, ME 04101

Dear Valued Customer,

Here at Mercy we take your healthcare seriously. In an effort to improve the care and services we
provide you with we are reviewing the way in which we deliver care specifically to our patients who are
receiving anticoagulant therapy, or blood thinners.
You have been identified as either currently receiving or having received a prescription for a blood
thinner and we would like to hear from you as to how we are doing providing the care you received
while on a blood thinner.
We truly value your input as we strive to provide with you with clinically excellent, compassionate care.
If you could take a moment to share your experiences and ideas by completing and returning the
enclosed form or sending us an email at mercyfeedback@emhs.org this will help us assess our service to
you.

Thank you,

[Name, Title]

52

Please take a moment and think about your most recent experience(s) with blood thinners as a Mercy
customer and answer the following questions:
1. I have a good understanding of the reason I am on a blood thinner
□ Yes □ No
Comments:_____________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
2. Someone has explained to me how the effectiveness of my blood thinner is measured
□ Yes □ No
Comments:_____________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
3. I have received all the information I need including foods to avoid, signs and symptoms of
bleeding, and when to call my doctor
□ Yes □ No
Comments:_____________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
4. I understand the importance and frequency of lab tests while on a blood thinner
□ Yes □ No
Comments:_____________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
5. I receive the results of lab tests and any changes in dosing in a timely manner
□ Yes □ No
Comments:_____________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
6. I would be interested in having the care of my blood thinner managed by a clinic focused solely
on blood thinner medications
□ Yes □ No
Comments:_____________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
Please feel free to provide any additional feedback or comments below and thank you for your time:
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
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Actions:
Guidelines for patient‐
self testing
Education
assessments
Location
Point‐of‐Care Testing
Policies and Protocols
Pharmacy
Collaboration
Primary Care
Providers
Electronic Health
Record (or external
tracking system)
Assessment/Education
Documentation
Flowsheet/Tracking
tool



Community



Health Care System
Resources and Policies

Self‐Management
Support

Delivery System
Design

Decision Support

Clinical Information
Systems










Prepared Proactive
Team:

Informed Activated
Patient:







Actions:
Patient
Letter/Survey
Referral Consent
Anticoagulation
Care Contract
Ongoing
educational
assessments
Periodic review of
plan of care







Resources
Social/Employment/Lifestyle
Beliefs/Attitudes/Motivation
Health Literacy
Level of Understanding



PRODUCTIVE INTERACTIONS







Anticoagulation
Management Service
Primary Care Physicians
Specialist Physicians
Visiting Nurse
Pharmacy
Lab







Improved
Outcomes

Actions:
Formal Training
Anticoagulation
Council
Communication
with PCP and
specialty care
Internal policies for
provision and
management of care
Tracking and
internal
performance
measures

(Wagner, 1998) 55
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